Emergent BioSolutions (EBS) Cash from Investing Activities (2010 - 2026)

Emergent BioSolutions' Cash from Investing Activities history runs 17 years deep, the most recent figure standing at -$2.4 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 104.03% year-over-year to -$2.4 million in Q1 2026; TTM through Mar 2026 was $7.5 million, a 96.16% decrease from a year earlier, with the FY2025 full-year figure at $69.4 million, down 44.57% from the prior year.
• Cash from Investing Activities grew to -$2.4 million in Q1 2026 per EBS's latest filing, from -$3.9 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $257.7 million in Q2 2023 and bottomed at -$271.6 million in Q3 2022.
• The 5-year median for Cash from Investing Activities is -$4.6 million (2024), against an average of $1.4 million.
• Across the five-year window, Cash from Investing Activities plunged 392.03% in 2022 and soared 902.8% in 2023, its largest moves.
• Year by year, Cash from Investing Activities stood at -$45.4 million in 2022, then surged by 74.89% to -$11.4 million in 2023, then soared by 350.88% to $28.6 million in 2024, then tumbled by 113.64% to -$3.9 million in 2025, then soared by 38.46% to -$2.4 million in 2026.
• Per Business Quant, the three latest EBS Cash from Investing Activities figures stand at -$2.4 million (Q1 2026), -$3.9 million (Q4 2025), and -$3.4 million (Q3 2025).